The exceptional and far-flung manifestations of heart failure in eisenmenger syndrome

Heart Failure Clinics

Volumn 10, Issue 1, 2014, Pages 91-104

  Opotowsky, Alexander R ^a   Landzberg, Michael J ^a   Beghetti, Maurice ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Congenital heart disease; Eisenmenger syndrome; Pulmonary hypertension; Systemic to pulmonary arterial shunts

Indexed keywords

AMBRISENTAN; BOSENTAN; HEMOGLOBIN; IRON; NIFEDIPINE; OXYGEN; PROSTAGLANDIN; SILDENAFIL; TADALAFIL; URIC ACID; VASODILATOR AGENT;

CARDIOVASCULAR FUNCTION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DYSPNEA; EISENMENGER COMPLEX; ERYTHROCYTOSIS; EXERCISE; FATIGUE; HEADACHE; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXEMIA; IMMUNE DEFICIENCY; INFECTIOUS COMPLICATION; IRON METABOLISM; IRON THERAPY; KIDNEY FUNCTION; LUNG FUNCTION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MUSCLE WEAKNESS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC PULMONARY SHUNT; TREATMENT INDICATION;

CONGENITAL HEART DISEASE; EISENMENGER SYNDROME; PULMONARY HYPERTENSION; SYSTEMIC-TO-PULMONARY ARTERIAL SHUNTS;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIAC SURGICAL PROCEDURES; CLASSIFICATION; DISEASE MANAGEMENT; EISENMENGER COMPLEX; EUROPE; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; IRON; MULTIPLE ORGAN FAILURE; OXYGEN INHALATION THERAPY; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; PULMONARY CIRCULATION; TRACE ELEMENTS;

EID: 84888026205     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2013.09.005     Document Type: Review

References (123)

1. Warnes C.A., Liberthson R., Danielson G.K., et al. Task force 1: the changing profile of congenital heart disease in adult life. JAm Coll Cardiol 2001, 37(5):1170-1175.
2. Marelli A.J., Mackie A.S., Ionescu-Ittu R., et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007, 115(2):163-172.
3. Opotowsky A.R., Siddiqi O.K., Webb G.D. Trends in hospitalizations for adults with congenital heart disease in the U.S. JAm Coll Cardiol 2009, 54(5):460-467.
4. Rodriguez F.H., Moodie D.S., Parekh D.R., et al. Outcomes of Heart Failure-Related Hospitalization in Adults with Congenital Heart Disease in the United States. Congenit Heart Dis 2012, [Epub ahead of print].
5. O'Leary J.M., Siddiqi O.K., de Ferranti S., et al. The Changing Demographics of Congenital Heart Disease Hospitalizations in the United States, 1998 Through 2010. JAMA 2013, 309(10):984-986.
6. Beghetti M. Congenital heart disease and pulmonary hypertension. Rev Port Cardiol 2004, 23(2):273-281.
7. Eisenmenger V. Die angeborenen defekte der kammerscheidwand des herzens. ZKlin Med 1897, 32(Suppl 11):1-28.
8. Taussig HB. Congenital Malformations of the Heart: The Commonwealth Fund; 1947.
9. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br Med J 1958, 2(5098):701-709.
10. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958, 2(5099):755-762.
11. Diller G.P., Dimopoulos K., Okonko D., et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 2005, 112(6):828-835.
12. Duffels M.G., Engelfriet P.M., Berger R.M., et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007, 120(2):198-204.
13. Duffels M., van Loon L., Berger R., et al. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition. Congenit Heart Dis 2007, 2(4):242-249.
14. Engelfriet P.M., Duffels M.G., Moller T., et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007, 93(6):682-687.
15. Peacock A.J., Murphy N.F., McMurray J.J., et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007, 30(1):104-109.
16. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173(9):1023-1030.
17. Berger R.M., Beghetti M., Humpl T., et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012, 379(9815):537-546.
18. Barst R.J., McGoon M.D., Elliott C.G., et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012, 125(1):113-122.
19. Van de Bruaene A., Delcroix M., Pasquet A., et al. The Belgian Eisenmenger syndrome registry: implications for treatment strategies?. Acta Cardiol 2009, 64(4):447-453.
20. Baraona F., Gurvitz M., Landzberg M.J., et al. Hospitalizations and mortality in the United States for adults with Down syndrome and congenital heart disease. Am J Cardiol 2013, 111(7):1046-1051.
21. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S43-S54.
22. Galie N., Manes A., Palazzini M., et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008, 68(8):1049-1066.
23. Schulze-Neick I., Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart-cleaning up a dog's dinner. Cardiol Young 2008, 18(1):22-25.
24. van Albada M.E., Berger R.M. Pulmonary arterial hypertension in congenital cardiac disease-the need for refinement of the Evian-Venice classification. Cardiol Young 2008, 18(1):10-17.
25. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
26. Galie N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537.
27. Oya H., Nagaya N., Uematsu M., et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J 2002, 143(4):739-744.
28. Diller G.P., Dimopoulos K., Broberg C.S., et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006, 27(14):1737-1742.
29. Barnea O., Austin E.H., Richman B., et al. Balancing the circulation: theoretic optimization of pulmonary/systemic flow ratio in hypoplastic left heart syndrome. JAm Coll Cardiol 1994, 24(5):1376-1381.
30. Wong C.K., Lau C.P., Leung W.H., et al. The use of nifedipine in patients with Eisenmenger's syndrome complicating patency of the arterial duct. Int J Cardiol 1989, 25(2):173-178.
31. Wong C.K., Yeung D.W., Lau C.P., et al. Improvement of exercise capacity after nifedipine in patients with Eisenmenger syndrome complicating ventricular septal defect. Clin Cardiol 1991, 14(12):957-961.
32. Hopkins W.E., Kelly D.P. Angiotensin-converting enzyme inhibitors in adults with cyanotic congenital heart disease. Am J Cardiol 1996, 77(5):439-440.
33. Warnes C.A., Williams R.G., Bashore T.M., et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. JAm Coll Cardiol 2008, 52(23):e1-e121.
34. Oldershaw P.J., Sutton M.G. Haemodynamic effects of haematocrit reduction in patients with polycythaemia secondary to cyanotic congenital heart disease. Br Heart J 1980, 44(5):584-588.
35. Van de Pette J.E., Guthrie D.L., Pearson T.C. Whole blood viscosity in polycythaemia: the effect of iron deficiency at a range of haemoglobin and packed cell volumes. Br J Haematol 1986, 63(2):369-375.
36. Horigome H., Hiramatsu Y., Shigeta O., et al. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. JAm Coll Cardiol 2002, 39(6):1072-1077.
37. Maurer H.M., McCue C.M., Robertson L.W., et al. Correction of platelet dysfunction and bleeding in cyanotic congenital heart disease by simple red cell volume reduction. Am J Cardiol 1975, 35(6):831-835.
38. Mauer H.M., McCue C.M., Caul J., et al. Impairment in platelet aggregation in congenital heart disease. Blood 1972, 40(2):207-216.
39. Territo M.C., Perloff J.K., Rosove M.H., et al. Acquired Von Willebrand Factor Abnormalities in Adults with Congenital Heart Disease: Dependence Upon Cardiopulmonary Pathophysiological Subtype. Clin Appl Thromb Hemost 1998, 4(4):257-261.
40. Rabinovitch M., Andrew M., Thom H., et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987, 76(5):1043-1052.
41. Gill J.C., Wilson A.D., Endres-Brooks J., et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986, 67(3):758-761.
42. Vincentelli A., Susen S., Le Tourneau T., et al. Acquired von Willebrand syndrome in aortic stenosis. NEngl J Med 2003, 349(4):343-349.
43. Diller G.P., van Eijl S., Okonko D.O., et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008, 117(23):3020-3030.
44. Smadja D.M., Gaussem P., Mauge L., et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009, 119(3):374-381.
45. Dinh Xuan A.T., Higenbottam T.W., Clelland C., et al. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1990, 99(1):9-10.
46. Oechslin E., Kiowski W., Schindler R., et al. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005, 112(8):1106-1112.
47. Martinez-Quintana E., Rodriguez-Gonzalez F., Fabregas-Brouard M., et al. Serum and 24-hour urine analysis in adult cyanotic and noncyanotic congenital heart disease patients. Congenit Heart Dis 2009, 4(3):147-152.
48. Sietsema K.E., Cooper D.M., Perloff J.K., et al. Dynamics of oxygen uptake during exercise in adults with cyanotic congenital heart disease. Circulation 1986, 73(6):1137-1144.
49. Dimopoulos K., Okonko D.O., Diller G.P., et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 2006, 113(24):2796-2802.
50. Sandoval J., Alvarado P., Martinez-Guerra M.L., et al. Effect of body position changes on pulmonary gas exchange in Eisenmenger's syndrome. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1070-1073.
51. Sietsema K.E., Cooper D.M., Perloff J.K., et al. Control of ventilation during exercise in patients with central venous-to-systemic arterial shunts. JAppl Physiol 1988, 64(1):234-242.
52. Yang-Ting S., Aboulhosn J., Sun X.G., et al. Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome. Congenit Heart Dis 2011, 6(2):139-146.
53. Ramakrishnan S., Juneja R., Bardolei N., et al. Nocturnal hypoxaemia in patients with Eisenmenger syndrome: a cohort study. BMJ Open 2013, 3(3). Available at:. http://www.biomedsearch.com/attachments/00/23/48/29/23482988/bmjopen-2012-002039.pdf.
54. Sandoval J., Aguirre J.S., Pulido T., et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001, 164(9):1682-1687.
55. Dimopoulos K., Diller G.P., Koltsida E., et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 2008, 117(18):2320-2328.
56. Scott H.W., Elliott S.R. Renal hemodynamics in congenital cyanotic heart disease. Bull Johns Hopkins Hosp 1950, 86(1):58-71.
57. Malizia E. Renal function and hemodynamics in primary and secondary polycythemia. Acta Med Scand 1956, 154(5):399-406.
58. Thron C.D., Chen J., Leiter J.C., et al. Renovascular adaptive changes in chronic hypoxic polycythemia. Kidney Int 1998, 54(6):2014-2020.
59. Dittrich S., Kurschat K., Lange P.E. Abnormal rheology in cyanotic congenital heart disease-a factor in non-immune nephropathy. Scand J Urol Nephrol 2001, 35(5):411-415.
60. Wilcox C.S., Payne J., Harrison B.D. Renal function in patients with chronic hypoxaemia and cor pulmonale following reversal of polycythaemia. Nephron 1982, 30(2):173-177.
61. Ross E.A., Perloff J.K., Danovitch G.M., et al. Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. Circulation 1986, 73(3):396-400.
62. Oya H., Nagaya N., Satoh T., et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000, 84(1):53-58.
63. Hayabuchi Y., Matsuoka S., Akita H., et al. Hyperuricaemia in cyanotic congenital heart disease. Eur J Pediatr 1993, 152(11):873-876.
64. Daliento L., Somerville J., Presbitero P., et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998, 19(12):1845-1855.
65. Niwa K., Perloff J.K., Kaplan S., et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. JAm Coll Cardiol 1999, 34(1):223-232.
66. Traustason S., Jensen A.S., Arvidsson H.S., et al. Retinal oxygen saturation in patients with systemic hypoxemia. Invest Ophthalmol Vis Sci 2011, 52(8):5064-5067.
67. Petersen R.A., Rosenthal A. Retinopathy and papilledema in cyanotic congenital heart disease. Pediatrics 1972, 49(2):243-249.
68. Rutter T.W., Mullin V. Pheochromocytoma in a patient with Eisenmenger's complex. Anesth Analg 1991, 73(4):496-498.
69. Lumbiganon P., Chaikitpinyo A. Antibiotics for brain abscesses in people with cyanotic congenital heart disease. Cochrane Database Syst Rev 2013, (3). CD004469.
70. Rosenthal A., Fellows K.E. Acute infectious sinusitis in cyanotic congenital heart disease. Pediatrics 1973, 52(5):692-696.
71. Kaur C., Ling E.A. Blood brain barrier in hypoxic-ischemic conditions. Curr Neurovasc Res 2008, 5(1):71-81.
72. Dedkov E.I., Perloff J.K., Tomanek R.J., et al. The coronary microcirculation in cyanotic congenital heart disease. Circulation 2006, 114(3):196-200.
73. Perloff J.K. The coronary circulation in cyanotic congenital heart disease. Int J Cardiol 2004, 97(Suppl 1):79-86.
74. Chugh R., Perloff J.K., Fishbein M., et al. Extramural coronary arteries in adults with cyanotic congenital heart disease. Am J Cardiol 2004, 94(10):1355-1357.
75. Fyfe A., Perloff J.K., Niwa K., et al. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol 2005, 96(2):283-290.
76. Savransky V., Nanayakkara A., Li J., et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007, 175(12):1290-1297.
77. Sluimer J.C., Daemen M.J. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. JPathol 2009, 218(1):7-29.
78. Martinez-Quintana E., Rodriguez-Gonzalez F., Nieto-Lago V., et al. Serum glucose and lipid levels in adult congenital heart disease patients. Metabolism 2010, 59(11):1642-1648.
79. Hopkins W.E. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005, 16(1):19-25.
80. Kalogeropoulos A.P., Border W.L., Georgiopoulou V.V., et al. Right ventricular function in adult patients with Eisenmenger physiology: insights from quantitative echocardiography. Echocardiography 2010, 27(8):937-945.
81. Becker-Grunig T., Klose H., Ehlken N., et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol 2013, 168(1):375-381.
82. Ammash N., Warnes C.A. Cerebrovascular events in adult patients with cyanotic congenital heart disease. JAm Coll Cardiol 1996, 28(3):768-772.
83. Broberg C.S., Bax B.E., Okonko D.O., et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. JAm Coll Cardiol 2006, 48(2):356-365.
84. Tay E.L., Peset A., Papaphylactou M., et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011, 151(3):307-312.
85. Broberg C.S., Jayaweera A.R., Diller G.P., et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol 2011, 107(4):595-599.
86. Wimmer M., Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc Drugs Ther 1992, 6(2):183-186.
87. Fernandes S.M., Newburger J.W., Lang P., et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003, 91(5):632-635.
88. Apostolopoulou S.C., Manginas A., Cokkinos D.V., et al. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart 2007, 93(3):350-354.
89. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Chest 2006, 129(4):1009-1015.
90. Christensen D.D., McConnell M.E., Book W.M., et al. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004, 94(2):261-263.
91. D'Alto M., Vizza C.D., Romeo E., et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart 2007, 93(5):621-625.
92. Diller G.P., Dimopoulos K., Kaya M.G., et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart 2007, 93(8):974-976.
93. Gatzoulis M.A., Rogers P., Li W., et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005, 98(1):147-151.
94. Kotlyar E., Sy R., Keogh A.M., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young 2006, 16(3):268-274.
95. Schulze-Neick I., Gilbert N., Ewert R., et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J 2005, 150(4):716.
96. Sitbon O., Beghetti M., Petit J., et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 2006, 36(Suppl 3):25-31.
97. van Loon R.L., Hoendermis E.S., Duffels M.G., et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?. Am Heart J 2007, 154(4):776-782.
98. Zuckerman W.A., Leaderer D., Rowan C.A., et al. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011, 107(9):1381-1385.
99. Chau E.M., Fan K.Y., Chow W.H. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007, 120(3):301-305.
100. Lu X.L., Xiong C.M., Shan G.L., et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther 2010, 28(6):350-355.
101. Tay E.L., Papaphylactou M., Diller G.P., et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol 2011, 149(3):372-376.
102. Zhang Z.N., Jiang X., Zhang R., et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart 2011, 97(22):1876-1881.
103. Mukhopadhyay S., Nathani S., Yusuf J., et al. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome-a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011, 6(5):424-431.
104. Singh T.P., Rohit M., Grover A., et al. Arandomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006, 151(4):851.e1-851.e5.
105. Gatzoulis M.A., Beghetti M., Galie N., et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008, 127(1):27-32.
106. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114(1):48-54.
107. Berger R.M., Beghetti M., Galie N., et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J Cardiol 2010, 144(3):373-378.
108. Diller G.P., Alonso-Gonzalez R., Dimopoulos K., et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol 2013, 167(3):840-847.
109. Dimopoulos K., Inuzuka R., Goletto S., et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010, 121(1):20-25.
110. Kempny A., Dimopoulos K., Alonso-Gonzalez R., et al. Six Minute Walk Test Distance and Resting Oxygen Saturation but not Functional Class Predict Outcome in Adult Patients with Eisenmenger Syndrome. Int J Cardiol 2013, [Epub ahead of print].
111. D'Alto M., Romeo E., Argiento P., et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012, 155(3):378-382.
112. Iversen K., Jensen A.S., Jensen T.V., et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010, 31(9):1124-1131.
113. Batista R.J., Santos J.L., Takeshita N., et al. Successful reversal of pulmonary hypertension in Eisenmenger complex. Arq Bras Cardiol 1997, 68(4):279-280.
114. Lin M.T., Chen Y.S., Huang S.C., et al. Alternative approach for selected severe pulmonary hypertension of congenital heart defect without initial correction-palliative surgical treatment. Int J Cardiol 2011, 151(3):313-317.
115. Burkhart H.M., Dearani J.A., Williams W.G., et al. Late results of palliative atrial switch for transposition, ventricular septal defect, and pulmonary vascular obstructive disease. Ann Thorac Surg 2004, 77(2):464-468. [discussion: 468-9].
116. Baruteau A.E., Serraf A., Levy M., et al. Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg 2012, 94(3):817-824.
117. Esch J.J., Shah P.B., Cockrill B.A., et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. JHeart Lung Transplant 2013, 32(4):381-387.
118. Labombarda F., Maragnes P., Dupont-Chauvet P., et al. Potts anastomosis for children with idiopathic pulmonary hypertension. Pediatr Cardiol 2009, 30(8):1143-1145.
119. Gorenflo M., Gu H., Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology 2010, 116(1):10-17.
120. Huang J.B., Liu Y.L., Yu C.T., et al. Lung biopsy findings in previously inoperable patients with severe pulmonary hypertension associated with congenital heart disease. Int J Cardiol 2011, 151(1):76-83.
121. Waddell T.K., Bennett L., Kennedy R., et al. Heart-lung or lung transplantation for Eisenmenger syndrome. JHeart Lung Transplant 2002, 21(7):731-737.
122. Reitz B.A., Wallwork J.L., Hunt S.A., et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. NEngl J Med 1982, 306(10):557-564.
123. Stoica S.C., McNeil K.D., Perreas K., et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001, 72(6):1887-1891.